Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for EDP-978 (KIT Inhibitor) in Chronic Spontaneous Urticaria. The expected timing is based on the latest available company guidance and may change.
11/17/25:- Nominated EDP-978 KIT inhibitor for chronic spontaneous urticaria; IND submission planned in Q1 2026. 02/09/26:- IND remains on track Q1 2026; Ph1 topline data expected Q4 2026; KIT preclinical data at AAAAI 2026. 04/13/26:- First participant dosed in Ph1 SAD/MAD trial. Topline Ph1 data expected Q4 2026. 05/11/26:- Detailed Ph1 SAD/MAD trial design described; enrolling 98 volunteers; AAAAI 2026 preclinical posters presented Feb 27-Mar 2, 2026. 08/10/26:- Ph1 SAD/MAD topline data remains expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.